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enkatasrikanth_meAbstract The purpose of this research was to apply statistical design for the preparation of a
gastric ﬂoating tablet (GFT) of propranolol HCl and to investigate the effect of formulation
variables on drug release and the buoyancy properties of the delivery system. The contents of
polyethylene oxide (PEO) WSR coagulant and sodium bicarbonate were used as independent
variables in central composite design of the best formulation. Main effects and interaction terms of
the formulation variables were evaluated quantitatively using a mathematical model approach
showing that both independent variables have signiﬁcant effects on ﬂoating lag time, % drug
release at 1 h (D1 h) and time required to release 90% of the drug (t90). The desired function was
used to optimize the response variables, each with a different target, and the observed responses
were in good agreement with the experimental values. FTIR and DSC studies of the statistically
optimized formulation revealed there was no chemical interaction between drug and polymer. The
statistically optimized formulation released drug according to ﬁrst order kinetics with a non-
Fickian diffusion mechanism. Evaluation of the optimized formulation in vivo in human volunteers
showed that the GFT was buoyant in gastric ﬂuid and that its gastric residence time was enhanced
in the fed but not the fasted state.
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Statistical design and evaluation of a GFT of propranolol HCl 611. Introduction
Drug absorption from the gastrointestinal tract (GIT) is a
complex process inﬂuenced by many variables. It has been
reported that the extent of drug absorption from the GIT is
related to contact time with the small intestinal mucosa.
Gastroretentive drug delivery systems are designed to retain
drug in the gastric region for several hours and assist in
improving sustained delivery of orally administered drugs
that have an absorption window in a particular region of
the GIT1. These systems provide continuous release of drug
before it reaches the absorption window and thereby enhance
bioavailability.
A variety of approaches have been adopted to retain dosage
forms in the gastric region, including mucoadhesive, ﬂoating,
expanding and magnetic systems, systems with modiﬁed shape
and those based on superporous hydrogels2. Among these,
the gastric ﬂoating drug delivery system (GFDDS) offers a
number of applications for drugs with poor bioavailability
because of a narrow absorption window in the upper part of
the GIT. It retains the dosage form at the site of absorption
and thus enhances the bioavailability3,4. This paper reports the
development and evaluation of an effervescent gastric ﬂoating
tablet (GFT) to prolong gastric retention.
In the present investigation, propranolol HCl was selected
as a model drug in the development of the GFT. Propranolol
HCl is a synthetic b-adrenoceptor blocker with the chemical
name 1-(1-methylethylamino)-3-(1-naphthyloxy)-propan-2-ol
hydrochloride and structure is shown in Fig. 1. It is used as
an antihypertensive, antianginal and antiarrhythmic agent and
for the treatment of migraine5,6. It is highly lipophilic and
almost completely absorbed after oral administration but
undergoes high ﬁrst-pass metabolism by the liver such that
only about 25% of drug reaches the systemic circulation7.
Propranolol HCl has a short half life (3–4 h) and is insoluble
in intestinal ﬂuids (acid soluble basic drug). Because of these
characteristics, it was selected as a model for drugs requiring
extended gastric retention.
Khattar et al.8 formulated a gastroretentive hydrodynami-
cally balanced capsule containing propranolol HCl that was
shown to be buoyant in vivo by endoscopy. In a more recent
study, Stru¨bing et al.9 investigated the ﬂoating mechanism and
in vitro dissolution behavior of a poly(vinyl acetate)-based
gastric ﬂoating tablet (GFT) with membrane controlled drug
delivery. A GFT containing propranolol HCl developed by
Jagdale et al.10 using various polymers (hydroxypropyl
methylcellulose, hydroxypropyl cellulose and xanthan gum)
was evaluated in vitro and in vivo buoyancy studies. Bodea and
Leucuta11 applied factorial design to optimize sustained
release pellets of propranolol HCl prepared using Eudragits
RS as release retarding agent by the conventional pan method.
The plasticizer concentration was taken as an independent
variable and the coating dispersion was applied to the pellets
in the coating pan.Figure 1 Structure of propranolol HCl.Despite this evident interest in GFDDS, the development
and evaluation of such a system containing propranolol HCl
and with polyethylene oxide (PEO) as retarding polymer has
not been reported. PEO is a hydrophilic polymer, which, in the
presence of water, controls the release of active moiety either
by swelling or swelling/erosion to form a hydrogel. Its wide-
spread use in formulations is a consequence of its physical and
chemical stability, compressibility, high swelling ability and
good solubility in water. In fact, PEO has been proposed as an
alternative to cellulose or other ethylene glycol derivatives in
the production of controlled release drug delivery systems12,13.
In the present investigation, response surface methodology
(RSM) was used to formulate a GFT of propranolol HCl
using PEO WSR coagulant as retarding polymer and sodium
bicarbonate as effervescing agent.
RSM is widely employed to optimize formulations with
suitable experimental design because it permits a deeper under-
standing of a process or product and has important applications
in establishing the robustness of that product. Central composite
design is a progression from factorial designs, which have been
widely used in response surface modeling and optimization14.
The objective of this study was to systematically investigate
the impact of several formulation variables on drug release
and buoyancy properties of a GFT containing propranolol
HCl as model drug. To achieve this objective, the quantity of
PEO and concentration of sodium bicarbonate were selected
as independent variables, while the ﬂoating lag time, drug
release at 1 h (D1 h) and time required to release 90% of drug
(t90) were taken as dependent variables. The ranges of these
formulation variables were chosen based on the results
obtained in preliminary studies conducted in our laboratory.
In this study, Design Expert software was used to give
information not only on the critical values required to achieve
the desired response but also the possible interactions of the
selected independent variables on the dependent variables.2. Materials and methods
2.1. Materials
Propranolol HCl was provided by Dr Reddy’s Laboratories Ltd.
(Hyderabad, India). PEO WSR coagulant, sodium bicarbonate
and magnesium stearate were kindly provided by Unichem
Laboratories Ltd. (Goa, India). All other reagents and chemicals
were analytical grade and used as received.
2.2. Experimental design
RSM aims to establish the relative importance of two or more
factors and also to indicate whether or not interaction occurs
between the factors and thereby affects the magnitude of the
response. Central composite design can be used to derive two
or more factors. A two-factor (X1, X2), three-level (1, 0, þ1)
design can be developed by inclusion of a central point.
Horizontal and vertical lines are drawn through the central
point to form the axes of a central composite design. Further
experiments are positioned along the axes at a distance a from
the central point and the points X2¼0, X1¼7a, and X1¼0,
X2¼7a are called axial points. For a two-factor design, the
domain becomes a circle centered on (0, 0) and passing
through the factorial points (1, 1), (þ1, 1), and so on.
Table 2 Presentation of real values of 3 levels for the
central composite design.
Formulation PEO WSR
coagulant quantity
X1 (mg)
Sodium bicarbonate
X2 (%, w/w)
PPEOR 01 71.72 10
PPEOR 02 80.00 5
PPEOR 03 80.00 15
PPEOR 04 100.00 2.93
PPEOR 05 100.00 17.07
PPEOR 06 100.00 10
PPEOR 07 100.00 10
PPEOR 08 100.00 10
PPEOR 09 100.00 10
PPEOR 10 100.00 10
PPEOR 11 120.00 5
PPEOR 12 120.00 15
PPEOR 13 128.28 10
Table 3 Formula of ﬂoating tablets containing 80 mg
propranolol HCl using central composite design (data are
mg per tablet).
Ingredient
(mg/tablet)
PEO
WSR
coagulant
Sodium
bicarbonate
Magnesium
stearate
Tablet
weight
PPEOR 01 71.72 17.28 2 171
PPEOR 02 80 8.5 1.5 170
PPEOR 03 80 28.5 1.5 190
PPEOR 04 100 5.5 2 187.5
PPEOR 05 100 38 2 220
PPEOR 06 100 20 2 202
PPEOR 07 100 20 2 202
PPEOR 08 100 20 2 202
PPEOR 09 100 20 2 202
PPEOR 10 100 20 2 202
PPEOR 11 120 11 2 213
PPEOR 12 120 35.5 2.5 238
PPEOR 13 128.28 23.22 2.5 234
Table 1 Experimental range and levels of the indepen-
dent variables.
Variable Range and level
1 0 þ1
PEO WSR coagulant amount
X1 (mg)
80 100 120
Sodium bicarbonate concentration
X2 (%, w/w)
5 10 15
Meka Venkata Srikanth et al.62This means that a has a value of 21/2 and all the axial points
are situated at 71.414 from the central point14.
In the present study, central composite design was
employed containing 2 factors evaluated at 3 levels with
experimental trials being performed at all 13 possible combi-
nations. The levels and the real values of the two independent
variables are shown in Tables 1 and 2, respectively. The
formulation variables evaluated were X1: quantity of PEO
WSR coagulant (mg); X2: concentration of sodium bicarbo-
nate (%, w/w) and the response variables were Y1: ﬂoating lag
time (s); Y2: D1 h (%); Y3: t90 (h).2.3. Preparation of the GFT of propranolol HCl
All the ingredients listed in Table 3 were accurately weighed
and passed through a # 40 (420 mm) sieve. Propranolol HCl
(80 mg) was geometrically mixed with PEO WSR coagulant
until a homogeneous blend was achieved. Sodium bicarbonate
was then added to the above blend followed by the lubricant,
magnesium stearate (1%, w/w). The ﬂow property of the ﬁnal
blend was found to be satisfactory to allow the mixture to be
directly compressed into tablets on a 16-station rotary tablet
punching machine (M/s. Cadmach Machinery, Co. Pvt. Ltd.,
India) using 8 mm round plain punches at a hardness of
4–6 kg/cm2.2.4. Evaluation of the GFT
2.4.1. In vitro buoyancy studies
The in vitro buoyancy of the GFT was determined in triplicate
as the ﬂoating lag time and total ﬂoating time using the
method of Srikanth et al15. The tablets were placed in 900 mL
0.1 mol/L HCl in a beaker and the time required to rise to the
surface and ﬂoat (ﬂoating lag time) and the duration of time
ﬂoating on the dissolution medium (total ﬂoating time) were
determined.
2.4.2. In vitro dissolution studies
Dissolution proﬁles of the GFT were determined in triplicate at
3770.5 1C using the USP XXIII dissolution test apparatus
(LABINDIA, Disso 2000)16. The paddle stirrer rotating speed
was 50 rpm and the dissolution medium was 900 mL 0.1 M
HCl. Samples (5 mL) were withdrawn with replacement at
ﬁxed time intervals and ﬁltered through a 0.45 mm preﬁlter.
The ﬁltered samples were then diluted with dissolution medium
(when necessary) and the absorbance measured at 289 nm.
2.4.3. Release kinetic
Several mathematical models can be tested to determine which
best describes the kinetics and mechanism of drug release from
ﬂoating tablets17–21. In the present study, the in vitro drug
release data was ﬁtted to the following mathematical models:
Zero order Qt ¼Q0 þ K0t ð1Þ
First order logC¼ logC02K1t=2:303 ð2Þ
Higuchi Qt ¼ k2t1=2 ð3Þ
HixsonCrowell cube root ðW1=30 W1=3t Þ ¼ kht ð4Þ
KorsemeyerPeppas Qt=Qs ¼ kptn ð5Þ
where Q0, Qt and Qp are the amounts of drug dissolved initially,
at time t and at timep, (in most cases, Q0¼0), C0 and C are the
concentrations of drug initially and at time t,W0 andWt are the
amounts of drug in the pharmaceutical dosage form initially and
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obtained from the linear curves of the respective models.
2.5. Statistical analysis and optimization
Data obtained from all GFT formulations were analyzed using
Design Expert software and used to generate the study design
and the response surface plots. Polynomial models, including
linear, interaction and quadratic terms were generated for all
the response variables using the software. The best ﬁtting
model was selected based on comparisons of several statistical
parameters, including the coefﬁcient of variation (CV), coefﬁ-
cient of determination (R2) and adjusted coefﬁcient of deter-
mination (adjusted R2) provided by Design Expert software. In
addition, analysis of variance (ANOVA) was used to identify
signiﬁcant effects of factors on response regression coefﬁcients.
The F test and P values were also calculated using the software.
The relationship between the dependent and independent
variables was further elucidated using response surface plots.
These plots are useful to study the effects of various factors on
the response at a given time and to predict the responses of
dependent variables at intermediate levels of independent
variables. Subsequently, a numerical optimization technique
using the desirability approach and a graphical optimization
technique using overlay plots were used to generate new
formulations with the desired responses.
2.6. Validation of the experimental design
To validate the chosen experimental design, the experimental
values of the responses were quantitatively compared with
predicted values and the relative error (%) calculated using the
following equation (Eq. 6):
Relative errorð%Þ ¼ ðPredicted valueExperiment valueÞ
=Predicted value 100% ð6Þ2.7. Characterization of the optimized formulation
2.7.1. Fourier transform infrared spectroscopy (FTIR)
FTIR is used to detect a drug-excipient interaction. FTIR
studies of potassium bromide pellets in the region 3500–
500 cm1 were performed in triplicate on drug, polymer and
statistically optimized formulation using a Shimadzu FTIR
8700 IR spectrophotometer.
2.7.2. Differential scanning calorimetry (DSC)
DSC is a useful tool to monitor the effect of additives on the
structure of a material and to obtain information about the
physicochemical interaction between drug and polymer22.
DSC of drug, polymer and statistically optimized formulation
were carried out using a Mettler Toledo Star SW 8.10, Model
no: DSC 822 instrument. In this process, samples (8–10 mg)
were weighed into aluminum pans and heated under nitrogen
from 5 to 250 1C.
2.8. In vivo buoyancy studies
2.8.1. Study protocol
A GFT containing propranolol HCl was designed to be
retained in the stomach and allow a slow delivery of drugin its absorption window to provide increased and more
reproducible bioavailability. Although this is the desired out-
come, the actual efﬁcacy in a biological system must be
evaluated. In the present investigation, X-ray spectroscopy
was used to evaluate the intragastric ﬂoating behavior of the
statistically optimized GFT in both the fasted and fed states.
The in vivo X-ray study of the ﬂoating ability and gastric
retention of the GFT was carried out in two human volunteers
administered the GFT with barium sulfate (BaSO4). Two
healthy male subjects with, respectively, ages 27 and 27 years,
weights 58 and 78 kg and heights 165 and 175 cm participated
in the study. The volunteers were judged healthy on the basis
of previous medical history, physical examination and routine
laboratory tests. The subjects were presented with full details
of the investigation, both verbally and in writing, prior
to providing written informed consent. The study was con-
ducted under the guidance of a radiologist after approval by
the Institutional Ethics Committee of Andhra University,
Visakhapatnam (India).
The statistically optimized GFT was administered to the
volunteers, one in the fasted state and the other in the fed
state. The fasted subject fasted overnight and then swallowed
the GFT with 200 mL water. No food was allowed for up to
3 h after dosing and the subject was not allowed to lie down
or sleep. A glass of water (200 mL) was given at hourly
intervals. The fed subject fasted overnight and in the morning
consumed a high calorie high fat breakfast with a total
caloriﬁc value of approximately 900 cal (slice of bread with
25 g butter—250 cal, 75 g chicken tikka—350 kcal, 40 g egg
omelette—150 kcal, fruit juice—150 cal). The GFT was admi-
nistered with 200 mL water 30 min after the meal. Again the
subject was not allowed to eat for up to 6 h but given a glass of
water (200 mL) at hourly intervals.
2.8.2. Preparation of GFT for in vivo studies
The optimized GFT containing barium sulfate (PPEORsoB)
was prepared by the direct compression method. The content
of propranolol HCl was reduced to 40 mg to allow incorpora-
tion of the barium sulfate (40 mg) in a tablet of the same
weight. The propranolol HCl was geometrically mixed with
the PEO WSR coagulant until a homogeneous blend was
achieved after which the barium sulfate and sodium bicarbo-
nate were added and the blend mixed and lubricated with
magnesium stearate (1%, w/w). The ﬁnal blend was directly
compressed into tablets as previously described.3. Results and discussion
3.1. In vitro buoyancy studies
All GFT passed physicochemical tests for weight variation,
drug content and friability. Floating lag time of all formulations
was within the range 6–210 s and results are given in Table 4.
All formulations ﬂoated in the 0.1 mol/L HCl for more than 7 h
showing good matrix integrity during this extended period of
time. The results showed that (1) as the concentration of PEO
WSR coagulant (X1) increased, the ﬂoating lag time decreased
due to the increasing hydrophilic nature of the polymer
allowing penetration of liquid through pores formed on the
surface of the tablet, and (2) the total ﬂoating time increased
due to swelling of the tablet which keeps it intact for a longer
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increased and the ﬂoating lag time decreased with increase in
the sodium bicarbonate concentration. Sodium bicarbonate is
necessary in formulations to make them ﬂoat. It does this
through reaction with acid to liberate CO2, which gets trapped
within the gel formed by hydration of polymer thus decreasing
the tablet density to below 1 g/cm3.3.2. In vitro dissolution studies
The percentage of propranolol HCl released from the pre-
pared GFT formulations is shown in Fig. 2. The in vitro
release of propranolol HCl from the formulations PPEOR 01,
02, 03 and 04 reached 100% in less than 10 h; release from
PPEOR 06–10 exhibited 100% at the end of the 12th hour;
release from PPEOR 05, 11, 12 and 13 required more than
12 h. The results show that drug release is retarded as the
amount of polymer and concentration of sodium bicarbonate
increase. This may be due to increased trapping of air in the
gelliﬁed surface of the tablet and increased trapping of carbon
dioxide.Table 4 Observed responses of PEO WSR coagulant
based formulations by central composite design (data are
mean values, n¼3).
Formulation X1 X2 Floating
lag time
(s)
D1 h
(%)
t90
(h)
Total
ﬂoating
time (h)
PPEOR 01 71.72 10 104 23.67 7.9 11
PPEOR 02 80.00 5 210 25.77 5.2 8
PPEOR 03 80.00 15 64 20.87 8.4 11
PPEOR 04 100.00 2.93 142 22.66 8.1 12
PPEOR 05 100.00 17.07 23 17.02 10.9 14
PPEOR 06 100.00 10 56 18.42 10 13
PPEOR 07 100.00 10 45 17.99 10.2 13
PPEOR 08 100.00 10 44 18.12 10.1 12
PPEOR 09 100.00 10 52 18.96 9.8 13
PPEOR 10 100.00 10 51 17.85 9.9 13
PPEOR 11 120.00 5 75 17.89 11.2 15
PPEOR 12 120.00 15 6 13.97 13.2 15
PPEOR 13 128.28 10 35 16.97 11.2 15
Figure 2 Dissolution proﬁles of ﬂoating tablet formulations (A)3.3. Release kinetics
Results of ﬁtting the dissolution proﬁles to the various kinetic
models are given in Table 5. Release from formulations
PPEOR 02, 04, 05, 11–13 followed zero order kinetics whereas
that from PPEOR 01, 03, 06–10 followed ﬁrst order kinetics.
Release from formulations PPEOR 01, 02, 04, 06–11 and 13
involved non-Fickian diffusion while that from others involved
an erosion mechanism. The results show that, as the concen-
tration of sodium bicarbonate exceeds 10% (w/w), the release
mechanism changes from diffusion to erosion. This may be due
to rapid disintegration of the tablets by increased formation of
carbon dioxide gas pockets in the gelliﬁed tablet matrix.3.4. Data analysis
All responses were ﬁtted to linear, interaction or quadratic
models using Design Expert software. A quadratic model is
suggested for ﬂoating lag time and D1 h, and a linear model for
t90. All dependent variable responses are shown in Table 6.
Using the synthetic polymer PEO WSR coagulant, 13 batches
of formulation were prepared within the experimental design to
obtain GFTs, which were evaluated for buoyancy properties. The
F value for ﬂoating lag time, D1 h and t90 were found to be 25.81,
34.15 and 33.17, respectively (Table 6) indicating that the models
are signiﬁcant. The values of Prob4F were found to be o0.05
for all responses again indicating that the models are signiﬁcant.
The response observations for ﬂoating lag time (coded units A, B,
AB and B2), D1 h (A, B and A
2) and t90 (A and B) were found to
be signiﬁcant model terms (A: PEO WSR coagulant; B: sodium
bicarbonate). The lack of ﬁt F values for ﬂoating lag time, D1 h
and t90 were found to be 22.87, 6.91 and 39.93, respectively
(Table 6) suggesting that the lack of ﬁt is signiﬁcant. The
calculated R2 value in the present model is close to zero
indicating a good model. In all cases, the adjusted R2 values
are in reasonable agreement with the predicted R2 values (0.9118
and 0.6499 for ﬂoating lag time, 0.9325 and 0.7553 for D1 h and
0.8690 and 0.8428 for t90). In all the cases precision values were in
the range 15–19 indicating an adequate signal and that the model
can be used to navigate within the design space (Table 7).
The application of response surface methodology yielded
the following regression equations (A: PEO, B: Sodium
bicarbonate):
Floating lag time¼ 49:60236:32A247:91Bþ 19:25AB
þ13:14A2 þ 19:64B2 ð7ÞPPEOR 01 to PPEOR 07 and (B) PPEOR 08 to PPEOR 13.
Table 5 Correlation coefﬁcient values and kinetics of drug release based on dissolution proﬁles of propranolol HCl GFT tablets.
Formulation Zero order First order Higuchi Hixson–Crowell Peppas
k0 r k1 r r r n r
PPEOR 01 9.8339 0.9767 0.2863 0.9936 0.9920 0.9749 0.6634 0.9933
PPEOR 02 15.548 0.9913 0.6057 0.9378 0.9851 0.9764 0.7462 1.0000
PPEOR 03 9.7564 0.9861 0.2577 0.9882 0.9911 0.9956 0.7049 0.9970
PPEOR 04 9.6698 0.9840 0.3565 0.9529 0.9942 0.9922 0.6777 0.9940
PPEOR 05 7.137 0.9844 0.2139 0.9739 0.9924 0.9952 0.7023 0.9975
PPEOR 06 8.2218 0.9850 0.2174 0.9911 0.9927 0.9917 0.7050 0.9971
PPEOR 07 8.0792 0.9851 0.2087 0.9919 0.9934 0.9734 0.6983 0.9986
PPEOR 08 8.1235 0.9843 0.2158 0.9921 0.9933 0.9990 0.6998 0.9984
PPEOR 09 8.1463 0.9835 0.2236 0.9863 0.9922 0.9787 0.6994 0.9956
PPEOR 10 8.1771 0.9822 0.2218 0.9927 0.9938 0.9914 0.7007 0.9977
PPEOR 11 7.1289 0.9795 0.2174 0.9673 0.9939 0.9938 0.6819 0.9965
PPEOR 12 6.3322 0.9839 0.1898 0.9766 0.9920 0.9967 0.7345 0.9978
PPEOR 13 7.0602 0.9866 0.1997 0.9775 0.9986 0.9958 0.6875 0.9994
k0: Zero order rate constant; k1: First order rate constant; r: Correlation coefﬁcient; n: Diffusion exponent.
Table 6 Summary of ANOVA results in analyzing lack of ﬁt (LOF) and pure error for the responses of GFT formulations.
Parameter Sum of squares df Mean square F value P value Prob4F Remark
Floating lag time (Quadratic model)
Model 33875.2 5 6775 25.81 0.0002 Signiﬁcant
Residual 1837.14 7 262.4
Lack of Fit 1735.94 3 578.6 22.87 0.006 Signiﬁcant
Pure Error 101.2 4 25.3
D1h (Quadratic model)
Model 117 5 23.4 34.15 o 0.0001 Signiﬁcant
Residual 4.7965 7 0.685
Lack of Fit 4.0206 3 1.34 6.909 0.0463 Signiﬁcant
Pure Error 0.7759 4 0.194
t90 (Linear model)
Model 40.391 2 20.2 33.166 o0.0001 Signiﬁcant
Residual 6.0891 10 0.609
Lack of Fit 5.9891 6 0.998 39.927 0.002 Signiﬁcant
Pure Error 0.1 4 0.025
df: degrees of freedom.
Table 7 Statistical parameters for the responses of the
GFT formulations.
Parameter Floating
lag time
D1 h (%) t90 (h)
Mean 69.7692 19.2431 9.7000
SD 16.2003 0.8278 0.7803
CV (%) 23.2198 4.3017 8.0446
R2 0.9486 0.9606 0.869
Adj R2 0.9118 0.9325 0.843
Pred R2 0.6499 0.7553 0.72306
Adeq
Precision
15.3070 18.2495 16.424
SD: Standard deviation; CV: Coefﬁcient of variation.
Statistical design and evaluation of a GFT of propranolol HCl 65D1h ¼ 18:2723:03A22:10Bþ 0:25ABþ 0:91A2 þ 0:67B2 ð8Þ
t90 ¼ 9:70þ 1:93Aþ 1:14B ð9ÞThe contour and response surface plots for all responses of all
formulation factors are shown in Figs. 3 and 4. The contour and
response plots of the response surface as a function of two factors
at a time, with all other factors ﬁxed, are more helpful in under-
standing both the main and interaction effects of the two factors.
To optimize all the responses with different targets, a
multicriteria decision approach (a numerical optimization
technique by the desirability function and a graphical optimi-
zation technique by the overlay plot) was used (Figs. 5 and 6).
The optimized formulation was obtained by applying con-
straints on dependent variable responses and independent
variables. The constraints were: Minimal ﬂoating lag time;
D1 ho20% (ﬁxed by the USP dissolution conditions16); t90 10–
11 h. These constrains are common for all the formulations.
The recommended concentrations of the independent variables
were calculated by the Design Expert software from the above
plots which has the highest desirability near to 1.0. The
extensive grid and feasibility searches provided that the
optimum formulations and the respectively desired function
Figure 3 Contour plots for the effect of PEO WSR coagulant (A) and sodium bicarbonate (B) on responses related to buoyancy.
Figure 4 Response plots for the effect of (A) amount of PEO WSR coagulant (mg) and (B) concentration of sodium bicarbonate
(%, w/w) on responses related to buoyancy.
Figure 5 Desirability for optimization of gastric ﬂoating tablets
of propranolol HCl. (A) amount of PEO WSR coagulant (mg)
and (B) concentration of sodium bicarbonate (%, w/w).
Figure 6 Overlay plot for optimization of gastric ﬂoating tablets
of propranolol HCl. (A) amount of PEO WSR coagulant (mg)
and (B) concentration of sodium bicarbonate (%, w/w).
Meka Venkata Srikanth et al.66response plot and overlay plot are as shown in Figs. 5 and 6,
where one solution was found with a highest desirability.
The optimum values of selected variables obtained using
Design Expert software were 106.32 mg PEO WSR coagulant
and 8.64% (w/w) sodium bicarbonate. The ﬁnal composition
comprised 80 mg propranolol HCl, 106.32 mg PEO WSR
coagulant, 17.68 mg sodium bicarbonate and 2 mg magnesium
stearate.
3.5. Evaluation and validation of the optimized formulation
The statistically optimized formulation (PPEORso) fulﬁlled all
the physicochemical criteria. In vitro buoyancy and dissolutionstudies were carried out on the prepared optimized formula-
tion to verify the theoretical prediction. The in vitro buoyancy
study showed that the ﬂoating lag time was 51 s and is in close
agreement with the model predictions (Table 8). The relative
errors (%) between the predicted and experimental values for
each response were calculated and the values found to be
within 5%. The experimental values were in agreement with
the predicted values conﬁrming the predictability and validity
of the model.
The optimized formulation gave ﬂoating lag time, D1 h and
t90 values of 51 s, 17.56% and 9.98 h, respectively. Drug
release from the optimized formulation followed ﬁrst order
kinetics with a non-Fickian diffusion mechanism.
Table 8 Comparison of predicted and observed responses for the statistically optimized formulation PPEORso.
Formulation Response Observed Predicted Relative error (%)
PPEORso Floating lag time (s) 51 51.58 1.12
D1 h (%) 17.56 17.99 2.39
t90 (h) 9.98 9.999 0.19
Figure 7 FTIR spectra of propranolol HCl (drug), PEO WSR coagulant and statistically optimized formulation PPEORso.
Figure 8 DSC thermograms of propranolol HCl (drug), PEOWSR
coagulant and statistically optimized formulation PPEORso.
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3.6.1. FTIR
The FTIR spectrum of PEO WSR coagulant showed a char-
acteristic alcoholic –OH stretch at 3433/cm, a –C–O–C asym-
metric stretch at 1260/cm and a –C–O–C symmetric stretch at
1060/cm. The FTIR spectrum of propranolol HCl showed a
characteristic secondary amine –NH stretch at 3280/cm, a C–H
stretch at 2964/cm, an aryl C¼C stretch at 1579/cm, an aryl
O–CH2 asymmetric stretch at 1240/cm, an aryl O–CH2 symmetric
stretch at 1030/cm and a peak at 798/cm due to alpha-substituted
naphathalene25 (Fig. 7). Corresponding peaks in PPEORso were
at 3280/cm, 2963/cm, 1577/cm, 1241/cm, 1031/cm and 797/cm.
The FTIR data indicate the absence of chemical interaction
between propranolol HCl and PEO WSR coagulant.Table 9 In vivo residence time and position in the GIT of
the optimized GFT of propranolol HCl containing barium
sulfate (PPEORsoB) in the fasted and fed states.
Time (h) Position of the tablet in GIT
Fed state Fasted state
0.5 Stomach Stomach
3 Stomach Small intestine
6 Stomach Disappeared from
gastric region
9 Disappeared from
gastric region3.6.2. DSC
The DSC thermograms of propranolol HCl, PEO and
PPEORso are shown in Fig. 8. The DSC thermograms of
pure propranolol HCl and PEO WSR coagulant show sharp
endothermic peaks at 167.56 and 69 1C, respectively, corre-
sponding to their melting points. PPEORso showed sharp
endothermic peaks at 166.23 and 68.9 1C representing drug
and polymer, respectively. A slight decrease in the energy
change of melting endotherm of PPEORso indicates a small
reduction in crystallinity, which may be due to a physical (but
not chemical) interaction between the drug and polymer.
Figure 9 X-ray photographs of gastric ﬂoating tablet of statistically optimized formulation PPEORsoB in a human volunteer in the
fasted state after (a) 0.5 h (b) 3 h and (c) 6 h.
Figure 10 X-ray photographs of gastric ﬂoating tablets of statistically optimized formulation PPEORsoB in a human volunteer in the
fed state after (a) 0.5 h (b) 3 h (c) 6 h and (d) 9 h.
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This study aimed to conﬁrm that the GFT would actually ﬂoat
and be retained in the stomach. A radiological method was
used to monitor the developed GFT in the gastric region of
human volunteers under fasting and fed conditions. It was
found that the GFT remained buoyant in gastric contents in
both fasted and fed states although ﬂoating and the gastric
retention time (GRT) depended on the feeding conditions as
shown in Table 9.
In the fasted state, the GFT was observed to be buoyant in
gastric ﬂuid after 0.5 h (Fig. 9a), to be present in the small
intestine after 3 h (Fig. 9b) and to have disappeared after 6 h
(Fig. 9c). Therefore, under these conditions, the ability to ﬂoat
did not enhance GRT. The rapid emptying was attributed to
periods of strong contractile activity which occurs under fasting
conditions every 1.5–2 h effectively sweeping undigested material
from the stomach. As a result, a GFT administered to fasted
subjects could be removed within as little as 1–2 h depending on
the strength of the motor induced contractile activity.
In the fed state, the GFT was observed to be buoyant in
gastric contents at 0.5 h (Fig. 10a), at 3 h (Fig. 10b) and at 6 h
(Fig. 10c) but to have disappeared at 9 h (Fig. 10d). Therefore,
in the fed state, the GRT was prolonged by 4–5 h compared to
the fasted state.
This study has demonstrated that, in the fasted state under
the inﬂuence of strong motor activity (the migrating myo-
electric complex), there is no enhancement of the GRT of the
GFT, whereas there was a prolonged GRT of approximately
6 h in the fed state.4. Conclusions
This study examines the preparation of a GFT containing
propranolol HCl using the synthetic polymer PEO WSR
coagulant as retarding polymer and sodium bicarbonate as gas
generating agent. A systematic study using a central composite
design revealed the most suitable content of PEO and sodium
bicarbonate in the GFT. The optimized formulation fulﬁlled all
the requirements of the target set and exhibited suitable values of
ﬂoating lag time, D1 h and t90. The intragastric behavior of the
statistically optimized GFT in human volunteers showed the
ﬂoatability of the tablet in gastric contents and a prolonged GRT
of approximately 6 h in the fed state. The present study clearly
indicates the applicability of statistical optimization techniques to
predict the composition of a formulation that gives optimum
product parameters.
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